Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6721 to 6735 of 7711 results

  1. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued [GID-TA10065]

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued [GID-TA10418]

    Technology appraisal guidance
    Discontinued

  3. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued [GID-TA10452]

    Technology appraisal guidance
    Discontinued

  4. Colon cancer (adjuvant) - irinotecan [ID379]

    In development [GID-TAG380] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Rucaparib for treating ovarian, fallopian tube or peritoneal cancer that has a BRCA mutation [ID1184]

    Discontinued [GID-TA10168]

    Technology appraisal guidance
    Discontinued

  6. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued [GID-TAG435]

    Technology appraisal guidance
    Discontinued

  7. Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

    Discontinued [GID-TA10018]

    Technology appraisal guidance
    Discontinued

  8. Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

    Discontinued [GID-TA10105]

    Technology appraisal guidance
    Discontinued

  9. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued [GID-TAG440]

    Technology appraisal guidance
    Discontinued

  10. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued [GID-TA10324]

    Technology appraisal guidance
    Discontinued

  11. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued [GID-TA10180]

    Technology appraisal guidance
    Discontinued

  12. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued [GID-TA10264]

    Technology appraisal guidance
    Discontinued

  13. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued [GID-TA10570]

    Technology appraisal guidance
    Discontinued

  14. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued [GID-TAG479]

    Technology appraisal guidance
    Discontinued

  15. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued [GID-TA10109]

    Technology appraisal guidance
    Discontinued